Top

Published in:

01-10-2021 | Metastasis | Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (P Lee and A Raldow, Section Editors)

Role of MR-guided Radiotherapy (MRgRT) in Colorectal Cancer

Authors: Ritchell van Dams, Ann C. Raldow, Percy Lee

Published in: Current Colorectal Cancer Reports | Issue 5/2021

Abstract

Purpose of Review

The current standard treatment for locally advanced or metastatic colorectal cancer often includes radiotherapy delivered under computed tomography (CT)–based image guidance. Magnetic resonance–guided radiotherapy (MRgRT) offers a substantial improvement in target and adjacent organ visualization and allows for real-time imaging throughout treatment to ensure target accuracy with each fraction. However, this technology is in its relative infancy, with many open questions regarding how to maximize the potential of this new treatment modality. We review the literature and share our institutional experience to highlight the strengths and limitations of MRgRT for treatment of colorectal cancer.

Recent Findings

MRgRT is safe and effective in both the locally advanced and metastatic settings. Dose can be safely escalated in locally advanced cases, potentially improving rates of pathologic complete response. Functional imaging offers insight into treatment response dynamics, opening the possibility for nonoperative management of select cases. Liver metastases can be treated to ablative doses with high rates of local control.

Summary

MRgRT has the potential to shift the paradigm of treatment for locally advanced and metastatic colorectal cancer. Improved target accuracy and real-time gating allows for dose prescriptions beyond what has been achievable with CT-based imaging, allowing for higher rates of tumor control with no significant increase in toxicity. Future work will focus on optimal dose fractionation schemes and functional radiographic assessment of tumor response.

Thompson MK, Poortmans P, Chalmers AJ, Faivre-Finn C, Hall E, Huddart RA, et al. Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? Br J Cancer. 2018;119:389–407. https://doi.org/10.1038/s41416-018-0201-z.CrossRefPubMedPubMedCentral

International Atomic Energy Agency. Planning national radiotherapy services: A practical tool, human health series No. 14, IAEA, Vienna. 2011

Mitchell DG, Snyder B, Coakley F, Reinhold C, Thomas G, Amendola M, et al. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol. 2006;24:5687–94. https://doi.org/10.1200/JCO.2006.07.4799.CrossRefPubMed

Chang JH, Lim Joon D, Nguyen BT, Hiew C-Y, Esler S, Angus D, et al. MRI scans significantly change target coverage decisions in radical radiotherapy for prostate cancer. J Med Imaging Radiat Oncol. 2014;58:237–43. https://doi.org/10.1111/1754-9485.12107.CrossRefPubMed

Klüter Se. Technical design and concept of a 0.35 T MR-Linac. Clin Transl Radiat Oncol. 2019;18:98–101. https://doi.org/10.1016/j.ctro.2019.04.007.CrossRefPubMedPubMedCentral

Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett SS, Werensteijn-Honingh AM, et al. Adaptive radiotherapy: the Elekta Unity MR-linac concept. Clin Transl Radiat Oncol. 2019;18:54–9. https://doi.org/10.1016/j.ctro.2019.04.001.CrossRefPubMedPubMedCentral

Thorwarth D, Low DA. Technical challenges of real-time adaptive MR-guided radiotherapy. Front Oncol. 2021;11:634507. https://doi.org/10.3389/fonc.2021.634507.CrossRefPubMedPubMedCentral

Kow AWC. Hepatic metastasis from colorectal cancer. J Gastrointest Oncol. 2019;10:1274–98. https://doi.org/10.21037/jgo.2019.08.06.CrossRefPubMedPubMedCentral

Ippolito E, Mertens I, Haustermans K, Gambacorta MA, Pasini D, Valentini V. IGRT in rectal cancer. Acta Oncol. 2008;47:1317–24. https://doi.org/10.1080/02841860802256459.CrossRefPubMed

10.

Nijkamp J, de Jong R, Sonke J-J, Remeijer P, van Vliet C, Marijnen C. Target volume shape variation during hypo-fractionated preoperative irradiation of rectal cancer patients. Radiother Oncol. 2009;92:202–9. https://doi.org/10.1016/j.radonc.2009.04.022.CrossRefPubMed

11.

Brierley JD, Dawson LA, Sampson E, Bayley A, Scott S, Moseley JL, et al. Rectal motion in patients receiving preoperative radiotherapy for carcinoma of the rectum. Int J Radiat Oncol Biol Phys. 2011;80:97–102. https://doi.org/10.1016/j.ijrobp.2010.01.042.CrossRefPubMed

12.

Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, et al. Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls. Int J Radiat Oncol Biol Phys. 2009;75:782–90. https://doi.org/10.1016/j.ijrobp.2008.11.031.CrossRefPubMed

13.

Van den Begin R, Kleijnen J-P, Engels B, Philippens M, van Asselen B, Raaymakers B, et al. Tumor volume regression during preoperative chemoradiotherapy for rectal cancer: a prospective observational study with weekly MRI. Acta Oncol. 2018;57:723–7. https://doi.org/10.1080/0284186X.2017.1400689.CrossRefPubMed

14.

Rogowski P, von Bestenbostel R, Walter F, Straub K, Nierer L, Kurz C, et al. Feasibility and early clinical experience of online adaptive MR-guided radiotherapy of liver tumors. Cancers. 2021;13:1523. https://doi.org/10.3390/cancers13071523.CrossRefPubMedPubMedCentral

15.

Hegde JV, Cao M, Yu VY, Kishan AU, Shaverdian N, Lamb J, et al. Magnetic resonance imaging guidance mitigates the effects of intrafraction prostate motion during stereotactic body radiotherapy for prostate cancer. Cureus. 2018;10:e2442. https://doi.org/10.7759/cureus.2442.CrossRefPubMedPubMedCentral

16.

Tetar SU, Bruynzeel AME, Lagerwaard FJ, Slotman BJ, Bohoudi O, Palacios MA. Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer. Phys Imaging Radiat Oncol. 2019;9:69–76. https://doi.org/10.1016/j.phro.2019.02.002.CrossRefPubMedPubMedCentral

17.

Prins FM, Stemkens B, Kerkmeijer LGW, Barendrecht MM, de Boer HJ, Vonken E-JPA, et al. Intrafraction motion management of renal cell carcinoma with magnetic resonance imaging-guided stereotactic body radiation therapy. Pract Radiat Oncol. 2019;9:e55-61. https://doi.org/10.1016/j.prro.2018.09.002.CrossRefPubMed

18.

Kim T, Lewis BC, Price A, Mazur T, Gach HM, Park JC, et al. Direct tumor visual feedback during free breathing in 0.35T MRgRT. J Appl Clin Med Phys. 2020;21:241–7. https://doi.org/10.1002/acm2.13016.CrossRefPubMedPubMedCentral

19.

Horvat N, Rocha CCT, Oliveira BC, Petkovska I, Gollub MJ. MRI of rectal cancer tumor staging, imaging techniques, and management. Radiographics. 2019;39:367–87. https://doi.org/10.1148/rg.2019180114.CrossRefPubMed

20.

Balyasnikova S, Brown G. Optimal imaging strategies for rectal cancer staging and ongoing management. Curr Treat Options Oncol. 2016;17:32. https://doi.org/10.1007/s11864-016-0403-7.CrossRefPubMedPubMedCentral

21.

Taylor FGM, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, et al. One millimetre is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer. Br J Surg. 2011;98:872–9. https://doi.org/10.1002/bjs.7458.CrossRefPubMed

22.

Boldrini L, Placidi E, Dinapoli N, Azario L, Cellini F, Massaccesi M, et al. Hybrid Tri-Co-60 MRI radiotherapy for locally advanced rectal cancer: an in silico evaluation. Tech Innov Patient Support Radiat Oncol. 2018;6:5–10. https://doi.org/10.1016/j.tipsro.2018.02.002.CrossRefPubMedPubMedCentral

23.••

Chiloiro G, Boldrini L, Meldolesi E, Re A, Cellini F, Cusumano D, et al. MR-guided radiotherapy in rectal cancer: first clinical experience of an innovative technology. Clin Transl Radiat Oncol. 2019;18:80–6. https://doi.org/10.1016/j.ctro.2019.04.006. The first clinical report using MRgRT for the treatment of rectal cancer.CrossRefPubMedPubMedCentral

24.

Burbach JPM, den Harder AM, Intven M, van Vulpen M, Verkooijen HM, Reerink O. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;113:1–9. https://doi.org/10.1016/j.radonc.2014.08.035.CrossRefPubMed

25.

Valentini V, Gambacorta MA, Cellini F, Aristei C, Coco C, Barbaro B, et al. The INTERACT trial: long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer. Radiother Oncol. 2019;134:110–8. https://doi.org/10.1016/j.radonc.2018.11.023.CrossRefPubMed

26.

Bonomo P, Lo Russo M, Nachbar M, Boeke S, Gatidis S, Zips D, et al. 1.5 T MR-linac planning study to compare two different strategies of rectal boost irradiation. Clin Transl Radiat Oncol. 2021;26:86–91. https://doi.org/10.1016/j.ctro.2020.11.016.CrossRefPubMed

27.

Habr-Gama A, São Julião GP, Vailati BB, Sabbaga J, Aguilar PB, Fernandez LM, et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy dose-escalation and consolidation chemotherapy. Ann Surg. 2019;269:102–7. https://doi.org/10.1097/SLA.0000000000002447.CrossRefPubMed

28.

Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501–13. https://doi.org/10.1016/S2468-1253(17)30074-2.CrossRefPubMed

29.

Fernandez LM, São Julião GP, Figueiredo NL, Beets GL, van der Valk MJM, Bahadoer RR, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22:43–50. https://doi.org/10.1016/S1470-2045(20)30557-X.CrossRefPubMed

30.••

Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg E-MK, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO) a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42. https://doi.org/10.1016/S1470-2045(20)30555-6. Landmark RCT demonstrating superior outcomes with total neoadjuvant therapy compared to standard of care treatment with adjuvant chemotherapy.CrossRefPubMed

31.

Conroy T, Bosset J-F, Etienne P-L, Rio E, François É, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–15. https://doi.org/10.1016/S1470-2045(21)00079-6.CrossRefPubMed

32.

Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007;25:4104–9. https://doi.org/10.1200/JCO.2007.11.9610.CrossRefPubMed

33.

Sun Y-S, Zhang X-P, Tang L, Ji J-F, Gu J, Cai Y, et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology. 2010;254:170–8. https://doi.org/10.1148/radiol.2541082230.CrossRefPubMed

34.

Shaverdian N, Yang Y, Hu P, Hart S, Sheng K, Lamb J, et al. Feasibility evaluation of diffusion-weighted imaging using an integrated MRI-radiotherapy system for response assessment to neoadjuvant therapy in rectal cancer. Br J Radiol. 2017;90:20160739. https://doi.org/10.1259/bjr.20160739.CrossRefPubMedPubMedCentral

35.

Fu J, Zhong X, Li N, Van Dams R, Lewis J, Sung K, et al. Deep learning-based radiomic features for improving neoadjuvant chemoradiation response prediction in locally advanced rectal cancer. Phys Med Biol. 2020;65:075001. https://doi.org/10.1088/1361-6560/ab7970.CrossRefPubMed

36.

Kim H, Pedersen K, Olsen JR, Mutch MG, Chin R-I, Glasgow SC, et al. Nonoperative rectal cancer management with short-course radiation followed by chemotherapy: a nonrandomized control trial. Clin Colorectal Cancer. 2021. https://doi.org/10.1016/j.clcc.2021.03.003.CrossRefPubMed

37.

Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66. https://doi.org/10.1016/j.radonc.2020.04.003.CrossRefPubMed

38.

van der Geest LGM, Lam-Boer J, Koopman M, Verhoef C, Elferink MAG, de Wilt JHW. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32:457–65. https://doi.org/10.1007/s10585-015-9719-0.CrossRefPubMed

39.

Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301. https://doi.org/10.2147/CLEP.S34285.CrossRefPubMedPubMedCentral

40.

Ruers T, Van Coevorden F, Punt CJA, Pierie J-PEN, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases results of a randomized phase II trial. J Natl Cancer Inst. 2017;109:djx015. https://doi.org/10.1093/jnci/djx015.CrossRefPubMedCentral

41.

Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD, Dorfman GS, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28:493–508. https://doi.org/10.1200/JCO.2009.23.4450.CrossRefPubMed

42.

Luterstein E, Cao M, Lamb JM, Raldow A, Low D, Steinberg ML, et al. Clinical outcomes using magnetic resonance-guided stereotactic body radiation therapy in patients with locally advanced cholangiocarcinoma. Adv Radiat Oncol. 2020;5:189–95. https://doi.org/10.1016/j.adro.2019.09.008.CrossRefPubMed

43.

Ohri N, Tomé WA, Méndez Romero A, Miften M, Ten Haken RK, Dawson LA, et al. Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol. 2021;110:188–95. https://doi.org/10.1016/j.ijrobp.2017.12.288.CrossRef

44.

Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018;126:519–26. https://doi.org/10.1016/j.radonc.2017.11.032.CrossRefPubMed

45.•

Rosenberg SA, Henke LE, Shaverdian N, Mittauer K, Wojcieszynski AP, Hullett CR, et al. A multi-institutional experience of MR-guided liver stereotactic body radiation therapy. Adv Radiat Oncol. 2019;4:142–9. https://doi.org/10.1016/j.adro.2018.08.005. An important early multi-institutional analysis of MRgRT for liver SBRT.CrossRefPubMed

46.

van Dams R, Wu TC, Kishan AU, Raldow AC, Chu F-I, Hernandez J, et al. Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: a prospective phase I trial. Radiother Oncol. 2021:Online ahead of print. https://doi.org/10.1016/j.radonc.2021.06.005.

47.

Gani C, Boeke S, McNair H, Ehlers J, Nachbar M, Mönnich D, et al. Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac – feasibility, workflow data and patient acceptance. Clin Transl Radiat Oncol. 2021;26:55–61. https://doi.org/10.1016/j.ctro.2020.11.014.CrossRefPubMed

48.

Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–8. https://doi.org/10.1200/JCO.2008.19.6329.CrossRefPubMed

49.

Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141:543–53. https://doi.org/10.1007/s00432-014-1833-x.CrossRefPubMed

50.

Goodman BD, Mannina EM, Althouse SK, Maluccio MA, Cárdenes HR. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol. 2016;6:86–95. https://doi.org/10.1016/j.prro.2015.10.011.CrossRefPubMed

51.

Méndez Romero A, Keskin-Cambay F, van Os RM, Nuyttens JJ, Heijmen BJM, IJzermans JNM, et al. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother. 2017;22:126–31. https://doi.org/10.1016/j.rpor.2016.10.003.CrossRefPubMed

52.

Boldrini L, Romano A, Placidi L, Mattiucci GC, Chiloiro G, Cusumano D, et al. Case report: first in human online adaptive MR guided SBRT of peritoneal carcinomatosis nodules: a new therapeutic approach for the oligo-metastatic patient. Front Oncol. 2020;10:601739. https://doi.org/10.3389/fonc.2020.601739.CrossRefPubMedPubMedCentral

53.

Tyran M, Jiang N, Cao M, Raldow A, Lamb JM, Low D, et al. Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy. Radiother Oncol. 2018;129:319–25. https://doi.org/10.1016/j.radonc.2018.08.009.CrossRefPubMed

54.

Mayinger M, Ludwig R, Christ SM, Dal Bello R, Ryu A, Weitkamp N, et al. Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis. Radiat Oncol. 2021;16:84. https://doi.org/10.1186/s13014-021-01813-6.CrossRefPubMedPubMedCentral

55.

Chow PE, Chu F-I, Agazaryan N, Cao M, Tyran M, Yang Y, et al. Dosimetric quality of online adapted pancreatic cancer treatment plans on an MRI-guided radiation therapy system. Adv Radiat Oncol. 2021;6:100682. https://doi.org/10.1016/j.adro.2021.100682.CrossRefPubMedPubMedCentral

56.

Parikh NR, Lee PP, Raman SS, Cao M, Lamb J, Tyran M, et al. Time-driven activity-based costing comparison of CT-guided versus MR-guided SBRT. JCO Oncol Pract. 2020;16:e1378–85. https://doi.org/10.1200/JOP.19.00605.CrossRefPubMed

Title: Role of MR-guided Radiotherapy (MRgRT) in Colorectal Cancer
Authors: Ritchell van Dams
Ann C. Raldow
Percy Lee
Publication date: 01-10-2021
Publisher: Springer US
Keywords: Metastasis
Radiotherapy
Colorectal Cancer
Colorectal Cancer
Published in: Current Colorectal Cancer Reports / Issue 5/2021
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI: https://doi.org/10.1007/s11888-021-00467-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer